WO2005030961A1 - 新規な神経幹細胞マーカー - Google Patents
新規な神経幹細胞マーカー Download PDFInfo
- Publication number
- WO2005030961A1 WO2005030961A1 PCT/JP2004/013221 JP2004013221W WO2005030961A1 WO 2005030961 A1 WO2005030961 A1 WO 2005030961A1 JP 2004013221 W JP2004013221 W JP 2004013221W WO 2005030961 A1 WO2005030961 A1 WO 2005030961A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- gene
- antibody
- neural stem
- stem cell
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5058—Neurological cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5073—Stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Definitions
- the present invention relates to a method for detecting neural stem cell Z progenitor cells from a tissue or cell population composed of a plurality of cell types.
- the present invention also provides a method for maintaining the characteristics of neural stem cell Z progenitor cells when a process or an operation for inducing differentiation is performed on a tissue or a cell population composed of a plurality of cell types,
- the present invention relates to a screening method for drugs, manipulations, and the like, which can induce neural stem cells Z precursor cells in a cell population.
- Non-Patent Document 1 the discovery of neural stem cells has made it possible to screen drugs that act on neural stem cells and divide them into functional neurons such as neurons and glia (non-patented). Reference 2).
- Non-Patent Document 1 Reynolds, B.A. et al. (1992) A multipotent EGF—responsive striatal embryonic progenitor cell produces neurons and astrocytes.J. Neurosci. 12: 4565-74
- Non-Patent Document 2 Roy, N. et al. (2000) In vitro neurogensis by neural progenitor cells isolated from the adult human hippocampus.Nat.Med. 6: 271-77
- Non-patent Document 3 Keyoung H.M.et al. (2001) High-yield selection and extraction of two promoters-- defined phenotyoes of neural stem cells from the fetal brain.Nat. Biotech. 19: 843-50
- Non-Patent Document 4 Miller F. et al. (1987) Isotyoes of alpha—tubulin are di fferentially regulated during neural maturation. J. Cell. Biol. 105: 3
- An object of the present invention is to find a new neural stem cell marker and to detect neural stem cell Z progenitor cells from a tissue or cell population composed of a plurality of cell types. It is to provide a method for sorting cells.
- NC1 gene was found as a gene specifically expressed in the spleen of a patient with familial persistent hyperinsulinemic hypoglycemia of infancy (PHHI). It has been shown that the gene is specifically expressed in the brain.
- PHHI familial persistent hyperinsulinemic hypoglycemia of infancy
- the present inventors have studied the function of the NC1 gene in more detail, and have found that this gene functions as a means for detecting neural stem cell Z precursor cells by the method described below.
- Neural stem cells can proliferate and repeat passages (self-renewal ability), and at the same time, can produce cells that constitute the central nervous system such as neuron-glial cells (probably iridani ability). Defined as cells of the undifferentiated nervous system.
- Neural stem cells A selective culture method (neurosphere method) of Z progenitor cells has been established by Weiss et al. (Science, 255, 1707 (1992)). 0 The method of Weiss et al. Is based on the mouse embryonic spinal cord and striatum.
- neural stem cell Z progenitor cells When cells of the central nervous system, including the obtained neural stem cell Z progenitor cells, are cultured in a serum-free medium supplemented with EGF (epidermal growth factor) or FGF2 (fibroblast growth factor 2), many cells are serum-free. Although damaged in the environment, neural progenitor cells Z progenitor cells proliferate under these culture conditions and form cell spheres (neurospheres)!
- EGF epidermal growth factor 2
- FGF2 fibroblast growth factor 2
- the present inventors have established a system in which neurospheres are formed from cells prepared from the spinal cord and forebrain of a human fetus and are differentiated into Euron-glia cells by culturing them in the presence of serum. .
- the expression of the NC1 gene was examined using this system, as described later, the expression of the neurosphere, that is, the expression of neural stem cells Z progenitor cells increased with the increase in neuron / glial cells.
- the present invention relates to a DNA having the nucleotide sequence of SEQ ID NO: 13 which can be used for detecting the expression of the NC1 gene. That is, DNA having the whole or a part of the nucleotide sequence of SEQ ID NO: 1; DNA having the nucleotide sequence of SEQ ID NO: 2 or SEQ ID NO: 3.
- the present invention also relates to a peptide having the amino acid sequence of SEQ ID NO: 416, which specifically reacts with an NC1 gene product and serves as an epitope of an antibody that can be used for detecting the expression of the NC1 gene. That is, a peptide having the amino acid sequence of SEQ ID NO: 4; a peptide having the amino acid sequence of SEQ ID NO: 5; a peptide having the amino acid sequence of SEQ ID NO: 6;
- the above antibody wherein the type of the antibody is a polyclonal antibody; or the above antibody, wherein the type of the antibody is a monoclonal antibody.
- the present invention provides a method for detecting the expression of the NC1 gene using at least one selected from the group consisting of the above DNAs, peptides and antibody proteins, and an index for the expression of the NC1 gene. And a method of screening for a drug that functions as a nerve factor. That is, a method for detecting a neural stem cell Z precursor cell using at least one selected from the group consisting of the above DNA, peptide, and antibody; functioning as a neural differentiation factor or a neural differentiation inhibitor using the above detection method. This is a method of screening for a drug.
- the method for detecting a neural stem cell Z precursor cell of the present invention comprises a DNA having any one of the nucleotide sequences of SEQ ID NOS: 13 and 13, a peptide having the amino acid sequence of any of SEQ ID NOs: 4-16, and the peptide as an antigen. Using at least one of the antibodies obtained
- the neural stem cell Z precursor cells targeted in the present invention may be any animal species as long as they are capable of differentiating into neurons having a function such as two-way glial cells in vitro or in vivo.
- the form, generation stage, and the like are not particularly limited. Desirably, it is derived from mammals, and further from humans from the viewpoint of clinical application.
- Examples of a method for detecting that a target gene is expressed in a certain tissue or cell include the Northern method.
- NC1 gene shows high expression in neural stem cells Z progenitor cells
- using the Northern method for example, using the DNA having all or a part of the nucleotide sequence of SEQ ID NO: 1 as a probe, Neural stem cells Z progenitor cells can be detected in living tissues or cell populations composed of multiple cell types.
- the DNA having the nucleotide sequence of SEQ ID NO: 1 can be obtained by PCR or the like.
- the DNA used as the probe is not limited to the DNA having the nucleotide sequence of SEQ ID NO: 1, and any probe that specifically recognizes the NC1 gene-derived mRNA can be used as the probe.
- probe labeling substances include radioactive substances such as 32 P and 35 S; enzymes such as alkaline phosphatase and horseradish peroxidase; and fluorescent substances such as fluorescein and isothiocynate. It is not limited to.
- Examples of the method for labeling the probe include a method of enzymatic binding, a method of chemically binding, and a method using an in vitro transcription system as used in Example 1 described below. It is not particularly limited to these methods.
- the method for detecting the expression of the target gene is not limited to the Northern method, but the same method can be performed by, for example, the RT-PCR method or the primer-extension method. be able to.
- a DNA having the base sequence of SEQ ID NO: 2 and a DNA having the base sequence of SEQ ID NO: 3 can be used as primers.
- the DNAs having the nucleotide sequences of SEQ ID NOs: 2 and 3 can be obtained by DNA synthesis, respectively.
- the primers are not limited to those described above, and may be any primer that amplifies a DNA fragment having a nucleotide sequence regarded as a nucleotide sequence derived from the NC1 gene or that specifically recognizes a transcription product of the NC1 gene. All can be used as primers.
- the Western blot method is used to detect the presence of a target protein in a living tissue or a plurality of cells using an antibody that specifically reacts with a gene product of a certain NC1 gene. It is possible to detect neural stem cell Z progenitor cells in a cell population consisting of these cell types.
- NC1 gene product is a protein having a power of 247 amino acids.
- Producing a protein as an antigen requires a slightly complicated production process even if genetic engineering techniques are used. Therefore, the present inventors have decided to use a peptide that can be easily prepared as an antigen, and have set forth a peptide having an amino acid sequence that has a possibility that the hydrophobicity, basicity, etc. of amino acid may also be epitope, as SEQ ID NO: A peptide having the amino acid sequence described in 416 was selected.
- the antigen for producing an antibody that reacts with the NC1 gene product is not limited to the peptide described here, but may be a whole or a part of the NC1 gene product having 247 amino acids.
- proteins or peptides containing amino acid sequences other than the NC1 gene product such as FLAG or Myc peptide, which function as tag sequences It is also possible to use tide as an antigen.
- the peptide used as the antigen in the present invention such as the peptide having the amino acid sequence of SEQ ID NO: 416, was prepared by a solid-phase method using a peptide synthesizer, and a method, form, and apparatus for force synthesis. Is not particularly limited.
- the antibody that reacts with the NC1 gene product is not particularly limited, and may be a polyclonal antibody or a monoclonal antibody.
- a method for producing a polyclonal antibody and a monoclonal antibody conventionally known methods can be used.
- tissue immunostaining method an immunoprecipitation method, and the like as a method for detecting the presence of the target protein.
- An antibody recognizing the NC1 gene product can be obtained by such a method. By using this, it is possible to detect neural stem cells and Z progenitor cells in a living tissue using a cell population composed of a plurality of cell types.
- the method for screening a drug functioning as a nerve shunting factor or a nerve shunting inhibitor according to the present invention uses the above-described method for detecting neural stem cell Z precursor cells.
- the following method is used to screen for a drug that functions as a nerve-inducing factor or a nerve-inhibiting factor. be able to.
- a drug having a desired activity can be screened using the number of neural stem cells contained in the culture system or the level of expression of the NC1 gene as a neural stem cell marker as an index. .
- the culture system for differentiating nerve cells is not particularly limited, as long as the neurosphere system is the most appropriate culture system in which the expression of the NC1 gene changes with the intensification. .
- Quality, or extracts that may contain them include chemically synthesized compounds, culture solutions of microorganisms and cultured cells, extracts of living organisms or tissues, etc. Not something.
- NC1 gene and NC1 protein of the present invention are considered to be involved in the process of sorting cells in the nervous system, and can be applied as neural stem cell markers capable of detecting and selecting neural stem cell Z precursor cells. .
- Probes used for detection of gene expression were prepared by an in vitro transcription system using a vector into which a DNA fragment corresponding to the NC1 gene was incorporated. Specifically, the following method was used. Oligonucleotides having an Xhol site added to the base sequence described in SEQ ID NO: 2 and the base sequence described in SEQ ID NO: 3 were used as primers. For type ⁇ , a supernatant obtained by heat-treating a part of a human fetal cDNA library manufactured by CLONTECH and precipitating the residue by centrifugation was used. Using the above primers and type I, a DNA fragment having the NC1 gene-specific sequence was amplified by PCR.
- Vector-1 Promega, pGEM-T Easy. This vector contains the base sequence described in SEQ ID NO: 1 as a probe fragment. Using this vector, a DIG-11-UTP (Roche Molecular Biochemicals) -labeled RNA probe was prepared by an in vitro transcription system.
- Tissue explants from human fetal forebrain and spinal cord were collected and subjected to neurosphere culture method (Reynolds, B.A. et al., (1992) Neurosci. 12: 4565-74; Vescovi, AL et al., (199 3) Neuron 11: 951-66; Reynolds, BA and Weiss, S., (1996) Dev Bi ol. 175: 1-13), a neurosphere consisting of human neural stem cells Z progenitor cells was cultured. The details of the culture method followed the method of Kanamura et al. (Kanemura, Y. et al., (2002) J. Neurosci. Res. 69: 869-79).
- the membrane is washed, reacted with Anti-Digoxigenin-AP, Fab Fragment (Roche Molecular Biochemicals), and detected for NCI gene expression by CDP-Star cnemilummes cent substrate (Amersham Bioscience). Was done.
- NC1 indicates a position corresponding to the mobility of NC1 gene-derived mRNA
- 28S rRNA indicates a position corresponding to the mobility of 28S ribosomal RNA.
- ⁇ BXPC3J is a human spleen cancer-derived cell line BXPC3
- ⁇ NTERA-2 '' is a human embryonic carcinoma cell line NTERA-2
- ⁇ Jurkat '' is a human T cell urkat
- ⁇ U251 '' is a human glioblastoma.
- the derived cell line U251 is shown.
- the prepared neurosphere is composed of neural stem cell Z progenitor cells.
- the differentiation-inducing group A is composed of tubulin Bill-positive cells having neuronal traits and GFAP (glial fibrillary acidic protein) -positive cells having astrocyte traits.In the differentiation-inducing group B, almost all cells are GFAP. It consists of positive cells.
- the expression of the NC1 gene in these culture systems was remarkably high in the neurosphere, and low in both the differentiation-inducing groups A and B (Fig. 1). This result indicates that the expression of the NC1 gene decreases in neuronal dystrocytes, which are elevated in neural stem cell Z progenitor cells.
- the NC1 gene specifically shows high expression in neural stem cell Z precursor cells, indicating that this gene can be applied as a neural stem cell marker.
- an antibody was produced that reacted with the NC1 gene product.
- a peptide having the amino acid sequence described in SEQ ID NO: 4, which is a partial peptide of the NC1 gene product was synthesized, and immunized to rabbits to obtain antiserum. It was confirmed by ELIS A that this antiserum reacted with the original peptide at a titer of 10,000 times or more, and was used as an antiserum containing an antibody against the NC1 gene product.
- the detection of the NC1 gene product by the Western method using the antiserum prepared in (1) was examined for the neurosp here prepared from human fetal neural tissue in which the expression of the NC1 gene was detected in Example 1. .
- detection of the NC1 gene product was performed by the Western blotting method for transformants in which the NCI gene expression vector was introduced into urkat cells and Jurkat cells in which the expression of the NC1 gene was not detected.
- a whole cell extract was prepared from these cells, and a cytoplasmic fraction and a nuclear fraction were further prepared using an N-XTRACT kit (manufactured by SIGMA).
- the sample prepared in (2) was heated at 95 ° C for 5 minutes, fractionated by SDS polyacrylamide gel electrophoresis, and transferred to a nitrocellulose membrane.
- the membrane is a blocking solution (5% After blocking with skim milk (Tris buffer containing 0.1% Tween-20), the antiserum prepared in (1) was added. After washing the membrane, an anti-Egret IgG antibody (manufactured by Amersham Bioscience) labeled with horseradish 'baroxidase was reacted, and the reacted fraction was detected using ECL (manufactured by Amersham Bioscience).
- lane 1 is electrophoresis of total RNA derived from urkat cells
- lane 2 is forcibly expressing the NC1 gene and electrophoresed of all RNA derived from ⁇ Jurkat cells.
- lane 1 shows the whole cell extract derived from ⁇ Jurkat cells in which the NC1 gene is forcibly expressed
- lane 2 shows the cytoplasmic fraction derived from ⁇ Jurkat cells in which the NC1 gene is forcibly expressed
- lane 3 shows the NC (1) Electrophoresis of the nuclear fraction derived from Jurkat cells in which the gene was forcibly expressed.
- Lane 4 shows the whole cell extract of neurosphere
- Lane 5 shows the cytoplasmic fraction of neurosphere
- Lane 6 shows the nucleus of neurosphere. The fraction was electrophoresed.
- the antiserum expressed the NC1 gene did not react with Jurkat cells (Fig. 2, lane 1).
- the NCI gene and NCI protein of the present invention are thought to be involved in the process of sorting cells in the nervous system, and can be applied as neural stem cell markers capable of detecting and selecting neural stem cell Z precursor cells. .
- FIG. 1 is a view showing the results of NC1 gene expression analysis by Northern method.
- NC1 indicates a position corresponding to the mobility of mRNA derived from the NC1 gene.
- FIG. 2 is a view showing the result of detection of an NC1 gene product forcibly expressed in urkat cells by a Western method.
- lane 1 total RNA derived from Pio urkat cells was expressed, and in lane 2, NC1 gene was forcibly expressed, and total RNA derived from ⁇ Jurkat cells was electrophoresed.
- FIG. 2 is a view showing the result of detection of an NC1 gene product by a Western method. Lanes 1 and 4 were electrophoresed with the whole cell extract, lanes 2 and 5 with the cytoplasmic fraction, and lanes 3 and 6 with the nuclear fraction.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Developmental Biology & Embryology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/571,268 US20070031894A1 (en) | 2003-09-12 | 2004-09-10 | Novel nerve stem cell marker |
EP04787861A EP1669453A4 (en) | 2003-09-12 | 2004-09-10 | NEW NERVE STEM CELL MARKER |
JP2005514168A JPWO2005030961A1 (ja) | 2003-09-12 | 2004-09-10 | 新規な神経幹細胞マーカー |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-321564 | 2003-09-12 | ||
JP2003321564A JP2005087018A (ja) | 2003-09-12 | 2003-09-12 | 新規な神経幹細胞マーカー |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005030961A1 true WO2005030961A1 (ja) | 2005-04-07 |
Family
ID=34385936
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/013221 WO2005030961A1 (ja) | 2003-09-12 | 2004-09-10 | 新規な神経幹細胞マーカー |
Country Status (4)
Country | Link |
---|---|
US (1) | US20070031894A1 (ja) |
EP (1) | EP1669453A4 (ja) |
JP (2) | JP2005087018A (ja) |
WO (1) | WO2005030961A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007174954A (ja) * | 2005-12-27 | 2007-07-12 | Tokyoto Igaku Kenkyu Kiko | 神経幹細胞の製造方法 |
JP2012029684A (ja) * | 2010-06-30 | 2012-02-16 | Cell Aid Kenkyusho:Kk | 細胞の製造方法 |
JP2014503194A (ja) * | 2010-11-15 | 2014-02-13 | ジャウ−ナン・リー | ヒト・トロホブラスト幹細胞からの神経幹細胞の生成 |
US9457053B2 (en) | 2012-11-30 | 2016-10-04 | Accelerated Biosciences Corp. | Methods of differentiating stem cells by modulating MIR-124 |
US9808490B2 (en) | 2014-11-26 | 2017-11-07 | Accelerated Biosciences Corp. | Induced hepatocytes and uses thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030028904A1 (en) * | 2001-04-19 | 2003-02-06 | Gumienny Tina L. | Genes involved in engulfment of dying cells and cell migration |
WO2003078631A1 (fr) * | 2002-03-15 | 2003-09-25 | Kaneka Corporation | Nouveaux genes |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6682888B1 (en) * | 2000-05-05 | 2004-01-27 | Incyte Corporation | Genes expressed in alzheimer's disease |
-
2003
- 2003-09-12 JP JP2003321564A patent/JP2005087018A/ja active Pending
-
2004
- 2004-09-10 US US10/571,268 patent/US20070031894A1/en not_active Abandoned
- 2004-09-10 EP EP04787861A patent/EP1669453A4/en not_active Withdrawn
- 2004-09-10 WO PCT/JP2004/013221 patent/WO2005030961A1/ja not_active Application Discontinuation
- 2004-09-10 JP JP2005514168A patent/JPWO2005030961A1/ja active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030028904A1 (en) * | 2001-04-19 | 2003-02-06 | Gumienny Tina L. | Genes involved in engulfment of dying cells and cell migration |
WO2003078631A1 (fr) * | 2002-03-15 | 2003-09-25 | Kaneka Corporation | Nouveaux genes |
Non-Patent Citations (3)
Title |
---|
DATABASE GENBANK [online] 12 July 2001 (2001-07-12), STRAUSBERG, R.: "Homo sapiens, KIAA0281 gene product, clone MGC:754 IMAGE:3535846, mRNA, complete cds", XP002983657, Database accession no. BC003051 * |
GUMIENNY, T.L. ET AL.: "CED-12/ELMO, a novel member of the CrkII/Dock180/Rac pathway, is required for phagocytosis and cell migration", CELL, vol. 107, no. 1, 2001, pages 27 - 41, XP002977555 * |
See also references of EP1669453A4 * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007174954A (ja) * | 2005-12-27 | 2007-07-12 | Tokyoto Igaku Kenkyu Kiko | 神経幹細胞の製造方法 |
JP2012029684A (ja) * | 2010-06-30 | 2012-02-16 | Cell Aid Kenkyusho:Kk | 細胞の製造方法 |
JP2014503194A (ja) * | 2010-11-15 | 2014-02-13 | ジャウ−ナン・リー | ヒト・トロホブラスト幹細胞からの神経幹細胞の生成 |
US9574173B2 (en) | 2010-11-15 | 2017-02-21 | Accelerated Biosciences Corp. | Generation of neural stem cells from human trophoblast stem cells |
US11254911B2 (en) | 2010-11-15 | 2022-02-22 | Accelerated Biosciences Corp. | Generation of neural stem cells from human trophoblast stem cells |
US11891623B2 (en) | 2010-11-15 | 2024-02-06 | Accelerated Biosciences Corp. | Generation of neural stem cells from human trophoblast stem cells |
US9457053B2 (en) | 2012-11-30 | 2016-10-04 | Accelerated Biosciences Corp. | Methods of differentiating stem cells by modulating MIR-124 |
US10294458B2 (en) | 2012-11-30 | 2019-05-21 | Accelerated Biosciences Corp. | Methods of differentiating stem cells by modulating miR-124 |
US11028366B2 (en) | 2012-11-30 | 2021-06-08 | Accelerated Biosciences Corp. | Methods of differentiating stem cells by modulating MIR-124 |
US9808490B2 (en) | 2014-11-26 | 2017-11-07 | Accelerated Biosciences Corp. | Induced hepatocytes and uses thereof |
US10765704B2 (en) | 2014-11-26 | 2020-09-08 | Accelerated Biosciences Corp. | Induced hepatocytes and uses thereof |
US11026979B2 (en) | 2014-11-26 | 2021-06-08 | Accelerated Biosciences Corp. | Human hepatocytes and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
EP1669453A1 (en) | 2006-06-14 |
US20070031894A1 (en) | 2007-02-08 |
EP1669453A4 (en) | 2007-12-12 |
JPWO2005030961A1 (ja) | 2008-02-14 |
JP2005087018A (ja) | 2005-04-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2360923C2 (ru) | Новый лиганд рецептора цитокина zcytor17 | |
US5635354A (en) | Method for describing the repertoires of antibodies (Ab) and of T-cell receptors (TcR) of an individual's immune system | |
Stam et al. | Identification of candidate transcriptional modulators involved in successful regeneration after nerve injury | |
Pruss et al. | Mitogens for glial cells: a comparison of the response of cultured astrocytes, oligodendrocytes and Schwann cells | |
JP2003501038A5 (ja) | ||
KR20140092905A (ko) | 방광암의 치료 및 진단을 위한 방법 및 조성물 | |
CA2269634A1 (en) | Reagents and methods useful for detecting diseases of the breast | |
CA2257821A1 (en) | Genes from 20q13 amplicon and their uses | |
Maximino et al. | Deregulated expression of cytoskeleton related genes in the spinal cord and sciatic nerve of presymptomatic SOD1G93A amyotrophic lateral sclerosis mouse model | |
CA2362527A1 (en) | A novel, prostate-specific gene for diagnosis, prognosis and management of prostate cancer | |
WO2005030961A1 (ja) | 新規な神経幹細胞マーカー | |
WO2007021004A1 (ja) | ドーパミン産生ニューロン増殖前駆細胞マーカーMsx1/2 | |
CA2232237A1 (en) | Reagents and methods useful for detecting diseases of the breast | |
KR101828812B1 (ko) | 줄기세포의 세포노화 검출용 키트 | |
KR101739104B1 (ko) | 뇌전증 관련 뇌 체성 유전 변이 및 이의 이용 | |
CN110386973B (zh) | 具有多种功能的蛋白多肽及其医药用途 | |
KR101577007B1 (ko) | 지방유래줄기세포의 분화능력 탐지 마커 및 이의 용도 | |
KR101547307B1 (ko) | 뇌전증 진단용 바이오마커 | |
Kuromitsu et al. | A unique downregulation of h2-calponin gene expression in Down syndrome: a possible attenuation mechanism for fetal survival by methylation at the CpG island in the trisomic chromosome 21 | |
KR101227434B1 (ko) | 유방암 줄기세포 특이적 마커인 cd44 단백질 표적용 펩타이드 및 이의 이용 | |
KR101603633B1 (ko) | EGF 또는 bFGF를 포함하는 배지에서 배양한 지방유래 줄기세포의 증식 및 치료능력 탐지 마커 및 이의 용도 | |
CN109182513B (zh) | 生物标志物scfd2在阿尔茨海默诊治中的应用 | |
KR101777590B1 (ko) | EGF 또는 bFGF를 포함하는 배지에서 배양한 지방유래 줄기세포의 증식 및 치료능력 탐지 마커 및 이의 용도 | |
KR101818819B1 (ko) | 뇌암 환자의 생존 기간 예측을 위한 정보 제공 방법 | |
KR102139784B1 (ko) | Gad 유전자의 프로모터를 포함하는 가바성 신경세포의 검출용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005514168 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004787861 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004787861 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007031894 Country of ref document: US Ref document number: 10571268 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10571268 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2004787861 Country of ref document: EP |